Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 12, 2012 - Issue 5
Submit an article Journal homepage
336
Views
20
CrossRef citations to date
0
Altmetric
Drug Profile

A review of cost–effectiveness of palivizumab for respiratory syncytial virus

Julia M Hussman Medical Outcomes and Research in Economics Research Group, Sunnybrook Research Institute, Toronto, ON, Canada
,
Abby Li Medical Outcomes and Research in Economics Research Group, Sunnybrook Research Institute, Toronto, ON, Canada
,
Bosco Paes Department of Pediatrics (Neonatal Division), McMaster University, Hamilton, ON, Canada
&
Krista L Lanctôt Medical Outcomes and Research in Economics Research Group, Sunnybrook Research Institute, Toronto, ON, Canada; Departments of Psychiatry and Pharmacology/Toxicology, University of Toronto, Toronto, ON, Canada. [email protected]
Pages 553-567 | Published online: 09 Jan 2014

References

  • Hall CB, Weinberg GA, Iwane MK et al. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 360(6), 588–598 (2009).
  • Centers for Disease Control. Respiratory syncytial virus – United States, July 2007–June 2011. MMWR Morb. Mortal. Wkly. Rep. 60(35), 1203–1206 (2009).
  • Nair H, Nokes DJ, Gessner BD et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375(9725), 1545–1555 (2010).
  • Nair H, Verma VR, Theodoratou E et al. An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children. BMC Public Health 11(Suppl. 3), S30 (2011).
  • American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 112(6 Pt 1), 1442–1446 (2003).
  • McLaurin K, Leader S. Growing impact of RSV hospitalizations among infants in the US, 1997–2002. Presented at: The Pediatric Academic Societies Annual Meeting. Washington, DC, USA, 14–17 May 2005.
  • Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140(6), 543–546 (1986).
  • Arnold SR, Wang EE, Law BJ et al. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr. Infect. Dis. J. 18(10), 866–869 (1999).
  • Bloemers BL, van Furth AM, Weijerman ME et al. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis – a prospective birth-cohort study. Pediatrics 120(4), e1076–e1081 (2007).
  • Kristensen K, Hjuler T, Ravn H, Simões EA, Stensballe LG. Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study. Clin. Infect. Dis. 54(6), 810–817 (2012).
  • Langley JM, Wang EE, Law BJ et al. Economic evaluation of respiratory syncytial virus infection in Canadian children: a Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. J. Pediatr. 131(1 Pt 1), 113–117 (1997).
  • Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA 282(15), 1440–1446 (1999).
  • Simon A, Prusseit J, Müller A. Respiratory syncytial virus infection in children with neuromuscular impairment. Open Microbiol. J. 5, 155–158 (2011).
  • Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch. Dis. Child. 94(2), 99–103 (2009).
  • Wilkesmann A, Ammann RA, Schildgen O et al. DSM RSV Ped Study Group. Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr. Infect. Dis. J. 26(6), 485–491 (2007).
  • Zachariah P, Ruttenber M, Simões EA. Hospitalizations due to respiratory syncytial virus in children with congenital malformations. Pediatr. Infect. Dis. J. 30(5), 442–445 (2011).
  • Zachariah P, Ruttenber M, Simões EA. Down syndrome and hospitalizations due to respiratory syncytial virus: a population-based study. J. Pediatr. 160(5), 827–31.e1 (2012).
  • Krilov LR. Respiratory syncytial virus disease: update on treatment and prevention. Expert Rev. Anti. Infect. Ther. 9(1), 27–32 (2011).
  • Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J et al. IRIS Study Group. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr. Infect. Dis. J. 27(9), 788–793 (2008).
  • Law BJ, Langley JM, Allen U et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr. Infect. Dis. J. 23(9), 806–814 (2004).
  • Sommer C, Resch B, Simões EA. Risk factors for severe respiratory syncytial virus lower respiratory tract infection. Open Microbiol. J. 5, 144–154 (2011).
  • Korppi M, Piippo-Savolainen E, Korhonen K, Remes S. Respiratory morbidity 20 years after RSV infection in infancy. Pediatr. Pulmonol. 38(2), 155–160 (2004).
  • Sigurs N, Aljassim F, Kjellman B et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 65(12), 1045–1052 (2010).
  • Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 162(1-2), 80–99 (2011).
  • DeVincenzo JP. The promise, pitfalls and progress of RNA-interference-based antiviral therapy for respiratory viruses. Antivir. Ther. (Lond.) 17(1 Pt B), 213–225 (2012).
  • Subramanian KN, Weisman LE, Rhodes T et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr. Infect. Dis. J. 17(2), 110–115 (1998).
  • Sáez-Llorens X, Castaño E, Null D et al. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group. Pediatr. Infect. Dis. J. 17(9), 787–791 (1998).
  • IMpact-RSV study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102(3 Pt 1), 531–537 (1998).
  • Feltes TF, Cabalka AK, Meissner HC et al. Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J. Pediatr. 143(4), 532–540 (2003).
  • Stein RT, Sherrill D, Morgan WJ et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 354(9178), 541–545 (1999).
  • Ruotsalainen M, Piippo-Savolainen E, Hyvärinen MK, Korppi M. Respiratory morbidity in adulthood after respiratory syncytial virus hospitalization in infancy. Pediatr. Infect. Dis. J. 29(9), 872–874 (2010).
  • Mejías A, Chávez-Bueno S, Ríos AM et al. Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob. Agents Chemother. 48(5), 1811–1822 (2004).
  • Mejías A, Chávez-Bueno S, Ríos AM et al. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob. Agents Chemother. 49(11), 4700–4707 (2005).
  • Simoes EA, Groothuis JR, Carbonell-Estrany X et al. Palivizumab Long-Term Respiratory Outcomes Study Group. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J. Pediatr. 151(1), 34–42, 42.e1 (2007).
  • Simões EA, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick L, Groothuis JR; Palivizumab Long-Term Respiratory Outcomes Study Group. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J. Allergy Clin. Immunol. 126(2), 256–262 (2010).
  • Smart KA, Lanctôt KL, Paes BA. The cost–effectiveness of palivizumab: a systematic review of the evidence. J. Med. Econ. 13(3), 453–463 (2010).
  • Prescott WA Jr, Doloresco F, Brown J, Paladino JA. Cost–effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review. Pharmacoeconomics 28(4), 279–293 (2010).
  • Rietveld E, Steyerberg EW, Polder JJ et al. Passive immunisation against respiratory syncytial virus: a cost–effectiveness analysis. Arch. Dis. Child. 95(7), 493–498 (2010).
  • Neovius K, Buesch K, Sandström K, Neovius M. Cost–effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden. Acta Paediatr. 100(10), 1306–1314 (2011).
  • Hampp C, Kauf TL, Saidi AS, Winterstein AG. Cost–effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch. Pediatr. Adolesc. Med. 165(6), 498–505 (2011).
  • Harris KC, Anis AH, Crosby MC, Cender LM, Potts JE, Human DG. Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective. Can. J. Cardiol. 27(4), 523e11–e15 (2011).
  • Resch B, Sommer C, Nuijten MJ et al. Cost–effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria. Pediatr. Infect. Dis. J. 31(1), e1–8 (2012).
  • Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. Br. Med. J. 313(7052), 275–283 (1996).
  • Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. Int. J. Technol. Assess. Health Care 21(2), 240–245 (2005).
  • Ofman JJ, Sullivan SD, Neumann PJ et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J. Manag. Care Pharm. 9(1), 53–61 (2003).
  • Banerji A, Lanctôt KL, Paes BA et al. Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants. Pediatr. Infect. Dis. J. 28(8), 702–706 (2009).
  • Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost–effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 104(3 Pt 1), 419–427 (1999).
  • Lofland JH, O’Connor JP, Chatterton ML et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost–effectiveness analysis. Clin. Ther. 22(11), 1357–1369 (2000).
  • Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur. J. Pediatr. 162(4), 237–244 (2003).
  • Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks’ gestation or earlier: hospitalization and economic implications of prophylaxis. Arch. Pediatr. Adolesc. Med. 154(1), 55–61 (2000).
  • Vogel AM, McKinlay MJ, Ashton T et al. Cost–effectiveness of palivizumab in New Zealand. J. Paediatr. Child Health 38(4), 352–357 (2002).
  • Fariña D, Rodríguez SP, Bauer G et al. Respiratory syncytial virus prophylaxis: cost effective analysis in Argentina. Pediatr. Infect. Dis. J. 21(4), 287–291 (2002).
  • Rodríguez SP, Fariña D, Bauer G. Respiratory syncytial virus prophylaxis in a high-risk population in Argentina: a cost–effectiveness analysis. Pediatr. Infect. Dis. J. 27(7), 660–661 (2008).
  • Rackham OJ, Thorburn K, Kerr SJ. The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations. Cardiol. Young 15(3), 251–255 (2005).
  • Chan PW, Abdel-Latif ME. Cost of hospitalization for respiratory syncytial virus chest infection and implications for passive immunization strategies in a developing nation. Acta Paediatr. 92(4), 481–485 (2003).
  • Simpson S, Burls A. A Systematic Review of the Effectiveness and Cost–Effectiveness of Palivizumab (Synagis®) in the Prevention of Respiratory Syncytial Virus (RSV) Infection in Infants at High Risk of Infection. University of Birmingham, Department of Public Health and Epidemiology, Birmingham, UK (2001).
  • Reeve CA, Whitehall JS, Buettner PG, Norton R, Reeve DM, Francis F. Cost–effectiveness of respiratory syncytial virus prophylaxis with palivizumab. J. Paediatr. Child Health 42(5), 253–258 (2006).
  • Elhassan NO, Sorbero ME, Hall CB, Stevens TP, Dick AW. Cost–effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch. Pediatr. Adolesc. Med. 160(10), 1070–1076 (2006).
  • Nuijten MJ, Wittenberg W. Cost–effectiveness of palivizumab in Spain: an analysis using observational data. Eur. J. Health Econ. 11(1), 105–115 (2010).
  • Lanctôt KL, Masoud ST, Paes BA et al. The cost–effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis. Curr. Med. Res. Opin. 24(11), 3223–3237 (2008).
  • Wang D, Cummins C, Bayliss S, Sandercock J, Burls A. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol. Assess. 12(36), iii, ix–x, 1–86 (2008).
  • Chirico G, Ravasio R, Sbarigia U. Cost–utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants. Ital. J. Pediatr. 35(1), 4 (2009).
  • Nuijten M, Lebmeier M, Wittenberg W. Cost–effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands. J. Med. Econ. 12(4), 291–300 (2009).
  • Resch B, Gusenleitner W, Nuijten MJ, Lebmeier M, Wittenberg W. Cost–effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clin. Ther. 30(4), 749–760 (2008).
  • Nuijten MJ, Wittenberg W, Lebmeier M. Cost–effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 25(1), 55–71 (2007).
  • Nuijten M, Lebmeier M, Wittenberg W. Cost–effectiveness of palivizumab in children with congenital heart disease in Germany. J. Med. Econ. 12(4), 301–308 (2009).
  • Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 114(6), 1606–1611 (2004).
  • Tam DY, Banerji A, Paes BA, Hui C, Tarride JE, Lanctôt KL. The cost–effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. J. Med. Econ. 12(4), 361–370 (2009).
  • Welliver RC Sr, Checchia PA, Bauman JH, Fernandes AW, Mahadevia PJ, Hall CB. Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Curr. Med. Res. Opin. 26(9), 2175–2181 (2010).
  • Krilov LR, Palazzi DL, Fernandes AW, Klein RW, Mahadevia PJ. Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States. Value Health 13(1), 77–86 (2010).
  • Smart KA, Paes BA, Lanctôt KL. Changing costs and the impact on RSV prophylaxis. J. Med. Econ. 13(4), 705–708 (2010).
  • Carta A, Briguglio I, Piras S et al. Quinoline tricyclic derivatives. Design, synthesis and evaluation of the antiviral activity of three new classes of RNA-dependent RNA polymerase inhibitors. Bioorg. Med. Chem. 19(23), 7070–7084 (2011).
  • Chapman J, Abbott E, Alber DG et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob. Agents Chemother. 51(9), 3346–3353 (2007).
  • Lundin A, Bergström T, Bendrioua L, Kann N, Adamiak B, Trybala E. Two novel fusion inhibitors of human respiratory syncytial virus. Antiviral Res. 88(3), 317–324 (2010).
  • Murineddu G, Murruzzu C, Pinna GA. An overview on different classes of viral entry and respiratory syncitial virus (RSV) fusion inhibitors. Curr. Med. Chem. 17(11), 1067–1091 (2010).
  • Ramilo O. Evolution of prophylaxis: MoAb, siRNA, vaccine, and small molecules. Paediatr. Respir. Rev. 10(Suppl. 1), 23–25 (2009).
  • DeVincenzo J, Lambkin-Williams R, Wilkinson T et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc. Natl Acad. Sci. USA. 107(19), 8800–8805 (2010).
  • Zamora MR, Budev M, Rolfe M et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am. J. Respir. Crit. Care Med. 183(4), 531–538 (2011).
  • Papenburg J, Carbonneau J, Hamelin MÈ et al. Molecular evolution of respiratory syncytial virus fusion gene, Canada, 2006–2010. Emerging Infect. Dis. 18(1), 120–124 (2012).
  • Zhu Q, McAuliffe JM, Patel NK et al. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J. Infect. Dis. 203(5), 674–682 (2011).
  • Tayyari F, Hegele RG. Identifying targets in the hunt for effective respiratory syncytial virus interventions. Expert Rev. Respir. Med. 6(2), 215–222 (2012).
  • Tayyari F, Marchant D, Moraes TJ, Duan W, Mastrangelo P, Hegele RG. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat. Med. 17(9), 1132–1135 (2011).
  • Gomez M, Mufson MA, Dubovsky F, Knightly C, Zeng W, Losonsky G. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatr. Infect. Dis. J. 28(7), 655–658 (2009).
  • Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol. Rev. 239(1), 149–166 (2011).
  • Groothuis JR, Hoopes JM, Jessie VG. Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention. Adv. Ther. 28(2), 91–109 (2011).
  • Schickli JH, Dubovsky F, Tang RS. Challenges in developing a pediatric RSV vaccine. Hum. Vaccin. 5(9), 582–591 (2009).
  • Schmidt AC. Progress in respiratory virus vaccine development. Semin. Respir. Crit. Care Med. 32(4), 527–540 (2011).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.